The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma
Sze Wai Fung(Chinese University of Hong Kong), ST Cheung(Immungenetics (Germany)), Charing C. N. Chong(National University of Singapore), Stephen L. Chan(Chinese University of Hong Kong), Phyllis F. Cheung(German Cancer Research Center), Kwok Wai Lo(Chinese University of Hong Kong), Carol Lee(Chinese University of Hong Kong), Chi Wai Yip(Chinese University of Hong Kong), Anthony W.H. Chan(Chinese University of Hong Kong), Chi-Hang Wong(Chinese University of Hong Kong), George Sai‐Wah Tsao(Chinese University of Hong Kong), Tan To Cheung(University of Hong Kong - Shenzhen Hospital), Linda W.C. Ng(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong)
Cited by 59
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k